Despite these limitations, the present study demonstrated that serum GGT could be a prognostic biomarker in men with mCRPC receiving docetaxel therapy, and that high serum GGT would be derived from overexpressed GGT in PC tissues. The gene discussed is GGT1; the disease is pachyonychia congenita.